Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu programs on hold in response to a case of nerve disease from a former parti | The phase 2 trial wrapped up in July 2023,

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and standalone flu inoculation, sending shares down sharply.

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates,

The stock drop also reflect concerns on whether the hold would impact Novavax's partnership with French drugmaker Sanofi, according to one analyst. Novavax said a participant enrolled in a mid-stage study of the combination vaccine last month reported symptoms of motor neuropathy,

Novavax stock fell sharply Wednesday after the U.S. Food and Drug Administration halted one of the vaccine maker’s clinical trials, citing safety concerns.Shares plummeted 18% to $10.32 in midday trading.

Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.The moves came as one patient who took the combination shot reported nerve damage.